HOOKIPA Pharma, Inc.
(NASDAQ : HOOK)

( )
HOOK After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
0.28%41.590.9%$960.31m
MRKMerck & Co., Inc.
0.19%78.870.6%$778.33m
JNJJohnson & Johnson
-0.15%138.400.7%$769.00m
BMYBristol-Myers Squibb Company
-1.20%46.291.4%$656.79m
LLYEli Lilly and Company
0.18%116.221.0%$521.76m
ABBVAbbVie, Inc.
0.44%79.812.2%$446.60m
NVSNovartis AG Sponsored ADR
-0.82%82.020.2%$208.94m
AZNAstraZeneca PLC Sponsored ADR
-0.64%37.541.3%$189.73m
GSKGlaxoSmithKline plc Sponsored ADR
-0.20%39.380.2%$99.07m
NVONovo Nordisk A/S Sponsored ADR Class B
0.98%47.250.1%$62.93m
SNYSanofi Sponsored ADR
-1.12%41.430.2%$47.37m
LCILannett Company, Inc.
0.00%6.0036.7%$10.13m
AKTXAkari Therapeutics Plc Sponsored ADR
-4.71%2.631.6%$3.88m
EPIXESSA Pharma Inc
0.94%2.160.1%$0.01m

Company Profile

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.